Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/10428194.2012.749470 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
Br J Haematol
January 2025
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains an option for young and fit chronic lymphocytic leukaemia (CLL) patients with high-risk disease features. However, allotransplanted patients are generally excluded from clinical trials, making data regarding the use of venetoclax after alloHSCT extremely rare. We report data from 7 CLL patients who received venetoclax after alloHSCT among 53 Italian centers.
View Article and Find Full Text PDFStrategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma.
Bone Marrow Transplant
November 2024
Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Several CD19 CAR-T-cell drugs are approved for safety and efficacy in advanced B-cell cancers with encouraging results. However, primary refractory and relapse are common. We critically analyze long-term data on efficacy of CD19 CAR-T-cell therapies in B-cell non-Hodgkin lymphomas from clinical trials with those of so-called real world data.
View Article and Find Full Text PDFInotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
J Clin Oncol
December 2024
Division of Hematology, Centre Hospitalier de Versailles, Université Versailles Paris-Saclay, Le Chesnay, France.
Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.
Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).
Prophylactic Cranial Irradiation prior to HCT for Acute Lymphoblastic Leukemia: To Boost or Not To Boost.
Clin Hematol Int
October 2024
Department of Pediatrics, Pediatric Bone Marrow Transplantation and Cellular Therapy Program King Hussein Cancer Center.
Article Synopsis
- * A study reviewed 166 patient records, focusing on 143 without prior central nervous system (CNS) involvement, and analyzed the outcomes of those who received TBI with or without CRB.
- * Results showed no significant differences in relapse rates or survival between patients with and without CRB, indicating that adding CRB may not provide extra benefits in preventing relapses after transplantation.
Fratricide-resistant CD7-CAR T cells in T-ALL.
Nat Med
December 2024
Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Article Synopsis
- A study involving 17 patients treated with autologous CAR T cells that target CD7 showed incredible success, with 16 patients achieving minimal residual disease-negative complete remission in less than a month, despite significant leukemia presence.
- The treatment had mild side effects, and a significant number of patients remained relapse-free, suggesting that anti-CD7 CAR T cell therapy is a promising option for T-ALL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!